BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27624914)

  • 1. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.
    Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
    J Neurooncol; 2016 Dec; 130(3):517-527. PubMed ID: 27624914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.
    Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Potter DM; Connelly AK; Dibridge SA; Whiteside TL; Okada H
    J Clin Oncol; 2014 Jul; 32(19):2050-8. PubMed ID: 24888813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
    Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
    Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.
    Okada H; Butterfield LH; Hamilton RL; Hoji A; Sakaki M; Ahn BJ; Kohanbash G; Drappatz J; Engh J; Amankulor N; Lively MO; Chan MD; Salazar AM; Shaw EG; Potter DM; Lieberman FS
    Clin Cancer Res; 2015 Jan; 21(2):286-94. PubMed ID: 25424847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
    Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
    J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.
    Fenstermaker RA; Ciesielski MJ; Qiu J; Yang N; Frank CL; Lee KP; Mechtler LR; Belal A; Ahluwalia MS; Hutson AD
    Cancer Immunol Immunother; 2016 Nov; 65(11):1339-1352. PubMed ID: 27576783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
    Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
    J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
    Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
    Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
    Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
    Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
    Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ
    J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.
    Hartman LL; Crawford JR; Makale MT; Milburn M; Joshi S; Salazar AM; Hasenauer B; VandenBerg SR; MacDonald TJ; Durden DL
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):451-7. PubMed ID: 24309609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
    Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
    BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain tumor immunotherapy with type-1 polarizing strategies.
    Okada H
    Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.
    Tsuji T; Sabbatini P; Jungbluth AA; Ritter E; Pan L; Ritter G; Ferran L; Spriggs D; Salazar AM; Gnjatic S
    Cancer Immunol Res; 2013 Nov; 1(5):340-50. PubMed ID: 24777970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.
    Müller S; Agnihotri S; Shoger KE; Myers MI; Smith N; Chaparala S; Villanueva CR; Chattopadhyay A; Lee AV; Butterfield LH; Diaz A; Okada H; Pollack IF; Kohanbash G
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
    Butowski N; Lamborn KR; Lee BL; Prados MD; Cloughesy T; DeAngelis LM; Abrey L; Fink K; Lieberman F; Mehta M; Ian Robins H; Junck L; Salazar AM; Chang SM
    J Neurooncol; 2009 Jan; 91(2):183-9. PubMed ID: 18850068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
    Okada H; Lieberman FS; Walter KA; Lunsford LD; Kondziolka DS; Bejjani GK; Hamilton RL; Torres-Trejo A; Kalinski P; Cai Q; Mabold JL; Edington HD; Butterfield LH; Whiteside TL; Potter DM; Schold SC; Pollack IF
    J Transl Med; 2007 Dec; 5():67. PubMed ID: 18093335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
    Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
    Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
    Rudnick JD; Sarmiento JM; Uy B; Nuno M; Wheeler CJ; Mazer MJ; Wang H; Hu JL; Chu RM; Phuphanich S; Black KL; Yu JS
    J Clin Neurosci; 2020 Apr; 74():187-193. PubMed ID: 32169363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
    Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
    Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.